Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neoplasms 1Melanoma 1Locally Advanced Rectal Adenocarcinoma 1Liposarcoma 1Leiomyosarcoma 1Esophageal Neoplasms 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × sotigalimab × Clear all
NCT04337931 2024-02-13

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Apexigen America, Inc.

Phase 2 Terminated
45 enrolled 14 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡